Exiqon A/S
Exiqon launches Exosome Isolation kits for analysis of biofluids

DGAP-News: Exiqon A/S /

06.05.2014 / 16:22

---------------------------------------------------------------------

Exiqon A/S (NASDAQ OMX: EXQ), a leading supplier of high-value gene expression
analysis products, today announced the launch of its miRCURY(TM) Exosome Isolation
kits for exosome isolation from various biofluids and cell media. 

Over the past few years the body of scientific literature has documented the
biological importance of exosomes. Exosomes play a key role in cell to cell
communication, cell migration, cell differentiation etc. Exosomes contain
protein and RNA and may be a preferred target for identification of new
biomarkers. However, the isolation of exosomes is challenged by the lack of
reproducibility, lack of specificity and tedious work processes. Exiqon's new
miRCURY(TM) Exosome Isolation Kits address these challenges. 

The miRCURY(TM) Exosome Isolation Kits ensure very high recovery of exosomes in
less than two hours and is based on non-toxic reagents. By the use of miRCURY(TM)
Exosome Isolation Kits, exosomes may be isolated from divers sources such as
serum, plasma, urine, CSF and cell culture media. 

'The miRCURY(TM) Exosome Isolation Kits consolidate Exiqon as the leading provider
of products for analysis of biofluids. With many auxiliary and integrated
products Exiqon are able to provide solutions for any RNA biomarker study in
biofluids' says Henrik M. Pfundheller, SVP, Sales and Marketing. 

The miRCURY(TM) Exosome Isolation Kits are optimized for use with the miRCURY(TM) RNA
Isolation Kits and the miRCURY LNA(TM) Universal RT microRNA PCR platform.
Exiqon's PCR offering now includes two new Exosome miRCURY LNA(TM) Universal RT
microRNA qPCR Focus Panels. The focus Panels contain LNA(TM) enhanced primer sets
targeting microRNAs typically found in exosomes from urine and CSF. The primer
sets have been thoroughly selected from a combination of literature mining and
Exiqon's internal diagnostic microRNA programs. 

Further details about the miRCURY(TM) Exosome isolation kits and the Exosome
microRNA Focus PCR Panel are available at www.exiqon.com/exosome-isolation-kits
and www.exiqon.com/exosome-mirna-pcr, respectively. 

Additional information:
Lars Kongsbak, President and CEO, tel. +45 4566 0888 (cell: +45 4090 2101)
Henrik M. Pfundheller, VP Sales & Marketing, tel. +45 4565 0420 (cell: +45 4090
2106) 

About Exiqon
Exiqon's products are based on the proprietary LNA(TM) technology. This technology
offers unique advantages for detection of miRNA biomarkers for life science
researchers, drug developers and cancer treating physicians working towards
personalizing medicine. Exiqon operates in two business areas: Exiqon Life
Sciences has established a position for itself as one of the market's leading
providers of miRNA research products for miRNA analysis in cells. Our research
products are used by academia, biotech and pharmaceutical companies around the
world to make groundbreaking discoveries about the correlation between gene
activity and the development of cancer and other diseases. Exiqon Life Sciences
is also collaborating with pharmaceutical companies in their effort to develop
new medicines based on miRNA as biological markers. Exiqon Diagnostics
collaborates with pharmaceutical and diagnostic companies to develop novel
molecular diagnostic tests for early detection of diseases which can help
physicians make treatment decisions. Exiqon is listed on the NASDAQ OMX in
Copenhagen. For more information about us, please visit www.exiqon.com.
News Source: NASDAQ OMX


End of Corporate News

---------------------------------------------------------------------

06.05.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language:    English       
Company:     Exiqon A/S    
 
 
             Denmark       
ISIN:        DK0060077758  
 
 
End of News    DGAP News-Service  
---------------------------------------------------------------------  
266759 06.05.2014